Amgen
World of DTC Marketing

Finally good news on the drug development front

Jul/26/2008 12:05
images
Amgen Inc. got an injection of upbeat news as its new bone-building drug was found to reduce the risk of spinal and hip fractures in a study of 7,800 women. Because D-mab is given by twice-yearly injection, analysts are uncertain whether it can surpass sales of the current generation of bone drugs known as bisphosphonates but this is where a great marketing program of DTC ads and physician messaging can really pay off. Read More...
|